Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Amino acids for renal protection: time to implement in clinical practice.

Korean journal of anesthesiology·2026

Same author

Sex-related mortality differences in septic shock: A propensity score-matched study.

Journal of critical care·2026

Same author

Association of duration of amino acids infusion and renal protection: a secondary analysis of the PROTECTION trial.

British journal of anaesthesia·2026

Same author

Neurocognitive outcomes: methodological clarifications.

Anaesthesia·2026

Same author

Acute normovolaemic haemodilution after cardiac surgery: a meta-analysis of randomised controlled trials.

British journal of anaesthesia·2026

Same author

Diabetes does not modify the renal-protective effect of intravenous amino acids infusion after cardiac surgery.

Journal of endocrinological investigation·2026

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Recombinant activated factor VII in cardiac surgery: a meta-analysis.

Alberto Zangrillo¹, Anna Mizzi, Giuseppe Biondi-Zoccai

¹Department of Cardiothoracic Anesthesia and Intensive Care, Università Vita-Salute San Raffaele, Milano, Italia.

Journal of Cardiothoracic and Vascular Anesthesia

|December 17, 2008

Summary

Recombinant activated factor VII (rFVIIa) may reduce surgical re-exploration after cardiac surgery but could increase stroke risk. Further research in large trials is needed to confirm these findings.

More Related Videos

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

Related Experiment Videos

Last Updated: Jun 27, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

Area of Science:

Cardiovascular Surgery
Hematology
Pharmacology

Background:

Perioperative bleeding increases patient morbidity and mortality.
Recombinant activated factor VII (rFVIIa) is a hemostatic agent with potential to reduce bleeding.
Previous trials on rFVIIa efficacy were underpowered.

Purpose of the Study:

To meta-analyze the efficacy and safety of rFVIIa in reducing perioperative bleeding.
To assess the impact of rFVIIa on surgical re-exploration, transfusion, thromboembolic events, and mortality.

Main Methods:

Meta-analysis of 5 clinical trials including 298 patients.
Studies involved patients with refractory blood loss, with rFVIIa doses ranging from 17-90 microg/kg.
Outcomes included survival, thromboembolic events, and surgical re-exploration.

Main Results:

A nonsignificant reduction in surgical re-exploration was observed (OR=0.25, p=0.42).
A trend towards increased perioperative stroke risk was noted (OR=3.17, p=0.09).
No significant effect on mortality was found (OR=0.96, p=0.90).

Conclusions:

rFVIIa may reduce surgical re-exploration in cardiac surgery.
Potential increased risk of adverse events like perioperative stroke requires further investigation.
Large randomized controlled trials are necessary to confirm these findings and guide clinical practice.